





Friday, 28 February 2025 | Pan Pacific Sonargaon Dhaka, Bangladesh



Organized by ________BANGLADESH SOCIETY FOR BREAST CANCER STUDY (BSBCS)

BANGLADESH BREAST CANCER CONFERENCE

<u>a</u> 66

۵


6

NGE 20% NGER GG 37 GANG

> > ilabes Raoni

60

TOUCHING LIVES to the Power of Cure



সেবার ব্যবধান পেরিয়ে ক্যান্সারকে দেবো হারিয়ে



PRELIMINARIES

- Welcome Message
- **& BSBCS Organization Members**
- Invited Speakers

SCIENTIFIC PROGRAM

- ♦ Inaugural Session
- Program Schedule
- ♦ Hall Map
- ♦ Abstracts

MEMORIES

- ♦ Bangladesh Breast Cancer Conference 2015
- ♦ Bangladesh Breast Cancer Conference 2017
- Bangladesh Breast Cancer Conference 2019
- Ontinuous Medical Education (CME)
- ♦ GCI-BSBCS Breast Tumour Board
- Annual General Meeting Program (AGM)
- ♦ 1st Breast Cancer Preceptorship Program
- 2nd Breast Cancer Preceptorship Program
- Screening Program
- ♦ Bangladesh Breast Cancer Conference 2022
- ♦ CRC Management Event
- ♦ 3rd Preceptorship Program on Sarcoma

WELCOME MESSAGE



ICE 2025 BANGLADESH BREAST GANCER CONFERENCE 2025 BANGLADESH BREAST GANCER



CHIEF GUEST

Bangladesh Breast Cancer Conference-2025

Professor of Medicine and Professor of Surgery Brown University, Lifespan Cancer Institute and the Legorreta Cancer Center, USA

It is indeed a matter of great pleasure that, Bangladesh Society for Breast Cancer Study (BSBCS) is going to organize 5th Bangladesh Breast Cancer Conference on 28th February 2025 at Pan Pacific Sonargaon Hotel, Dhaka.

Breast Cancer has turned out to be one of the top category cancers and has ranked as the third deadly on the list for both men and women in Bangladesh. Around 12,764 patients are newly diagnosed with Breast Cancer each year and mortality rate has been increased to 6,846. And this situation is getting worse day by day. According to International Agency for Research on Cancer (IARC), 65.5% of Breast Cancer Patients are delayed in their diagnosis by more than six months due to unawareness of the people, improper screening and furthermore poor socioeconomic infrastructure and atmosphere which is uprising the incidents in Bangladesh.

I offer my heartiest gratitude to the organizing committee of Bangladesh Breast Cancer Conference 2025 for taking such good steps and creating a room of knowledge for our oncologists.

I wish a grand success to BSBCS and hope all the participants will have a great time over the event.



PATRON

Bangladesh Society for Breast Cancer Study (BSBCS)

Ex-President
SAARC Federation of Oncology
& Chairperson of Oncology Club of
Bangladesh, Director (Rtd)
National Institute of Cancer and
Research Hospital, Dhaka

Distinguished Guests, Esteemed Colleagues, and Honorable Delegates,

Good morning, and a warm welcome to each of you. It is a privilege to stand before you at this significant Breast Cancer Conference here in Dhaka, Bangladesh. I extend my heartfelt appreciation to our esteemed speakers, delegates, and participants both local and international who have joined us for this vital gathering.

This conference serves as a crucial platform for surgeons, medical oncologists, radiation oncologists, medical physicists, and allied specialists to stay at the forefront of breast cancer management. Our primary focus is to explore the latest advancements in early detection, treatment strategies, and patient-centered care, while strengthening collaboration in our shared mission to combat this disease.

The impact of this event is profound. It provides an exceptional opportunity for medical professionals to engage with global experts, gain cutting-edge knowledge, and exchange best practices in breast cancer care. These insights will directly contribute to enhancing clinical practices, improving patient outcomes, and fostering a stronger, multidisciplinary approach to treatment.

As we embark on these discussions and workshops, I encourage each of you to actively participate—ask questions, share ideas, and collaborate. The knowledge and connections you cultivate here will not only benefit your practice but also advance breast cancer care in Bangladesh and beyond.

Once again, thank you all for being here. I look forward to the inspiring conversations and groundbreaking solutions that will emerge from this conference. Together, we can make a meaningful difference in the fight against breast cancer.

1

Professor Dr. M.A. Hai



PATRON

Bangladesh Society for Breast Cancer Study (BSBCS)

Past President Bangladesh College of Physician and Surgeons & Medical Advisor of Square Hospital Limited

Seeing the 5th International Conference on Breast Cancer titled as 'Bangladesh Breast Cancer Conference 2025 on 28th February 2025 is greatly delightful and encouraging.

Breast cancer is the most prevalent cancer among women worldwide and in Bangladesh as well.

According to reports, Bangladeshi women between the age of 30-44 years have the maximum risk of getting breast cancer (19.3 per 100000). It has become a hidden burden which accounts for almost 7% cancer death among women.


One of the important reasons of high morbidity and mortality is lack of screening program for early detection of disease. Lack of awareness, improper information about the course of treatment and inability to afford costly treatment all contribute and complicate further management. Lack of multidisciplinary approach and trained skilled nurses also make comprehensive care to breast cancer patients difficult.

Being a patron of the organizing committee for the Bangladesh Breast Cancer Conference 2025 is an honor. Bangladesh Society for Breast Cancer Study (BSBCS) has my heartfelt gratitude for organizing this international conference.

I strongly expect this conference will give us current knowledge on breast cancer management and mark a turning point for participants in applicable sectors. I congratulate the attendees and organizers on the event's outstanding success.



Prof. Dr. Sanawar Hossain



PRESIDENT

Bangladesh Society for Breast Cancer Study (BSBCS)

Consultant, Oncology & Radiotherapy, Bangladesh Specialized Hospital Ltd. Past Managing Director & Head, Department of Radiation Oncology Ahsania Mission Cancer & General Hospital (Rtd.) Professor of Radiation Oncology National Institute of Cancer Research Hospital (NICRH)


Welcome to the 5th Breast Cancer Conference, organized by the Bangladesh Society for Breast Cancer Study. This event reflects our commitment to advancing breast cancer research, awareness, and treatment.

Today, we gather to discuss the latest advancements in diagnostics, treatment, and patient care, while emphasizing early detection and equitable healthcare access. Your participation is key to driving progress in the fight against breast cancer.

I sincerely thank our organizing committee, sponsors, and all contributors, including our esteemed invited faculties from the USA, UK, Australia, Singapore, and other Asian countries, for their invaluable support. Let's collaborate, learn, and work toward a future where breast cancer is no longer life-threatening.

Glandhay

Prof. Dr. Qamruzzaman Chowdhury



VICE PRESIDENT

Society for Breast Cancer Study (BSBCS)

Sn. Consultant
Oncology & Radiotherapy Center
Square Hospitals Limited. Dhaka

I would like to grab this moment to welcome you all to the 5th Bangladesh Breast Cancer Conference 2025, which will be hosted on 28th February 2025 at Pan Pacific Sonargaon in Dhaka, on behalf of the organizing committee.

In Bangladesh, the incidence of breast cancer patients is rising at an alarming pace, especially among women after the cervical cancer. Males also have a probability of developing breast cancer. As a result, we have planned this conference so that everyone may have a thorough understanding of the most recent developments in treating breast cancer as well as the many aspects of illness management.

We are thankful and blessed to have speakers from several nations participating in this conference, who will serve as keynote speakers in various sessions and share their expertise in radiation oncology, medical oncology, breast surgery, breast pathology, and palliative care. Additionally, our home specialists will discuss their methods of treating breast cancer as well as their experiences in the field.

Without the outstanding assistance of our stakeholders, organizing a grant event like this would not have been possible, thus I think their names have to be acknowledged. All the pharmaceutical companies and diagnostic labs deserve my sincere gratitude for their kind assistance. Moreover, we appreciate the tireless assistance, support, and guidance provided by our committed employees, coworkers, friends, and families during the preparation and execution of this event. Besides that, we would like to express our gratitude to the print and electronic media for attending and covering the event.

I hope and think that this event will be able to convey broad knowledge to treat breast cancer, and through the dynamic engagement with each other from the various nationalities will inspire the sharing of ideas and knowledge, which I feel is beneficial for all of us. Last but not least, I want to express my hope and belief that we will all enjoy the conference and our hospitality in the stunning city of Dhaka, the center of Bangladeshi culture, on behalf of the organizing committee for the fourth BBCC 2025.

BSBCS

ORGANIZATION MEMBERS



DR. M A HAI Patron



DR. SANAWAR HOSSAIN Patron



DR.

QAMRUZZAMAN

CHOWDHURY

President



DR. MD. SALIM REZA Vice-President



MAJ. GEN. DR. MD. AZIZUL ISLAM Founder Member



DR.
SAJJAD
MOHAMMAD YUSUFF
Founder Member



DR.
FERDOUS ARA BEGUM
Executive Member



DR.

ARUNANGSHU DAS

General Secretary



DR. MD.

ARIFUR RAHMAN

Organizing Secretary

BSBCS

ORGANIZATION MEMBERS



DR. MD.

ASTEFCHAR HUSSAIN

Executive Member



DR. ARMAN REZA CHOWDHURY Office Secretary



DR.

LUBNA MARIAM

Education, Research and
Statistic Secretary



DR.
LATIFA SULTANA
Press &
Publication Secretary



DR. MD. NURUNNABI Financial Secretary



DR. S. M.

KHODEZA

NAHAR BEGUM

Executive Member



DR. A F M ANWAR HOSSAIN Executive Member



DR.
SHAFATUJJAHAN
Executive Member



DR.
SADIA SHARMIN
Executive Member

BSBCS

ORGANIZATION MEMBERS



DR. MD. NIZAMUL HAQUE Executive Member



DR.
FARIAH SHARMEEN
Executive Member



DR.
ALIYA SHAHNAZ
Executive Member



DR. ASM SHARIFUL ISLAM JHONNY
Executive Member



DR.

MASUDUL HASAN ARUP

Executive Member



DR. S M ROKONUZZAMAN Executive Member



DR.
SHARMIN SUMI
Executive Member



FARJANA KHAN Executive Member



A. S. M. SHAIFUL ISLAM Executive Member

INVITED SPEAKERS

PROF. DR. DON S. DIZON MD, FACP, FASCO Professor of Medicine & Surgery, Brown University Director, Pelvic Malignancies Program Lifespan Cancer Institute, Director, Medical Oncology Rhode Island Hospital





PROF. DR. IAN KUNKLER Consultant Clinical Oncology Edinburgh Cancer Centre University of Edinburgh, Edinburgh Scotland, UK

PROF. DR. ISMAIL JATOI

MD, PhD, FACS

Dale H. Dorn Chair in Surgery

Professor, Division of Surgical Oncology

and Endocrine Surgery University of

Texas Health Science Center





PROF. PETER SCHMID FRCP, MD, PhD Professor of Cancer Medicine Royal college of Physicians Centre lead, Group leader

PROF. DR. PAUL MAINWARING MBBS, MD, FRACP Co-Founder Executive Chairman & CEO XING Group Holdings Pty Ltd Brisbane, QLD Australia Consultant, Medical Oncologist ICON Cancer Care





DR. NICHOLAS ZDENKOWSKI BMed, FRACP, PhD Medical Oncologist, Hunter Valley Oncology Newcastle Australia Conjoint Senior Lecturer University of Newcastle, Australia

PROF. RAJESH BALAKRISHNAN MD, DNB (Radiation Oncology) Professor and Head of Unit III Department of Radiation Oncology

Christian Medical College, Vellore, India





DR. JABED IQBAL
Associate Professor
Senior Consultant
Department of Anatomical Pathology
Singapore General Hospital

DR. MD. ZAKER ULLAH Consultant Oncoplastic Breast & General Surgeon The Harley Street Clinic The Holly Private Hospital Barts Health NHS Trust





17/ 17/ 17/ 17/ 17/

(V)

JOANNE NGEOW YUEN YIE BMedSci, MBBS, FRCP, MPH, FAMS Associate Professor Senior Consultant, Division of Medical Oncology National Cancer Centre, Singapore

DR. MA JUN Consultant Division of Medical Oncology National Cancer Centre Singapore





DR. SEE HUI TI Senior Consultant Medical Oncologist Parkway Cancer Centre Singapore DR. TAN SI YING
Consultant Surgical Oncologist
in the Department of Breast Surgery
in both Singapore General
Hospital and National Cancer Centre, Singapore





DR. GRACE KUSUMAWIDJAJA Professor Consultant Radiation Oncology National Cancer Centre, Singapore

DR. AMAR DESHPANDE Senior Surgical Oncologist TATA Memorial Center Mumbai, India





DR. DODUL MONDAL
Director & Clinical Administrator
Department of Radiation Oncology
Max Super Speciality Hospital
Saket, Delhi, India

PROF. GOLAM ABU ZAKARIA Professor of Clinical Engineering University of Applied Sciences Koethen, Germany





DR. RASHMI CHAND
Consultant radiologist and
Incharge of Oncoradiology
Apollo Multispeciality Hospital, Kolkata

ZUBIN RUSSY MASTER Sr. Principal Radiation Physicist National Cancer Centre Singapore





PRE CONFERENCE SCHEDULE

27 FEBRUARY 2025

LIVE SURGERY

CONFERENCE HALL (DMCH)

8:00 AM - 2:30 PM

BREAST CANCER SURGERY

Moderator

Prof. Dr. Ismail Jatoi | Dr. Md Zaker Ullah | Prof. Dr. Salma Sultana

Prof. Dr. Ahmed Sayeed | Prof. Dr. Saif Uddin Ahmed

Panel of Expert

Prof. Dr. Mizanur Rahman | Prof. Dr. A F M Anwar Hossain Prof. Dr. Ravhana Awwal Sumi | Prof. Dr. Feroze Ouader

Chairperson

Prof.Dr. M A Maiid

RADIOTHERAPY SESSION

SURMA

4.00 PM - 5.30 PM

Speaker

Dr. Dodul Mondal | Prof. Dr. Raiesh Balakrishnan

Panel of Expert Prof. Dr. Don S Dizon | Dr. Hasan Murshed

Chairperson

Prof. Dr. Ian Kunkler Moderator

Dr. Shariful Islam Jhonny

RADIOLOGY SESSION

PADMA

Speaker

Dr. Rashmi Chand

Panel of Expert

Prof. Dr. Sharmin Akhtar Rupa | Prof. Brig Gen (Retd.) Jahangir Alam

Chairperson

Prof. Brig Gen Dr. S M A Al-Muid (Rtd.) Moderator Dr. Shafatujjahan

5.30 PM - 7.00 PM

PATHOLOGY SESSION

SURMA

5.30PM - 7.00PM

Speaker

Prof. Dr. Jabed Igbal | Prof. Dr. S M Khodeza Nahar Begum

Panel of Expert

Prof. Dr. Salauddin Ahmed | Dr. Joanne Ngeow Yuen Yie

Dr. Farida Ariuman | Prof. Dr. Paul Mainwaring

Chairperson

Prof. Dr. Mohammad Golam Mostafa Moderator

Dr. Fariah Sharmeen

INAUGURAL SESSION

09:00 AM - 09:30 AM
PAN PACIFIC SONARGAON DHAKA, BANGLADESH

BANGLADESH BREAST CANCER CONFERENCE

TOPICS

Welcome Address by Vice President

SPEAKER

Dr. Md. Salim Reza

TOPICS

Address by Patron

SPEAKER

Prof. Dr. Sanawar Hossain

TOPICS

Address by Patron

SPEAKER

Prof. Dr. M A Hai

TOPICS

Address by Special Guest

SPEAKER

Humaira Islam, PhD

TOPICS

Address by Special Guest

SPEAKER

Prof. Dr. Ismail Jatoi

TOPICS

Address by Chief Guest

SPEAKER

Prof Dr Don S Dizon

TOPICS

Address by President

SPEAKER

Prof. Dr. Qamruzzaman Chowdhury

SESSION NAVIGATOR

Dr. Latifa Sultana

PROGRAM SCHEDULE

SESSION 01

PLENARY 01 | BALL ROOM

Time	Topics	Speaker
09:30 AM - 10:00 AM	Management of TNBC	Prof. Dr. Don S. Dizon
10:00 AM - 10:30 AM	Estrogen Receptor Negative and Triple Negative Breast Cancer: Epidemiological and Surgical Considerations	Prof. Dr. Ismail Jatoi
10:30 AM - 11:00 AM	Update on adjuvant radiotherapy for early breast cancer, focussing on the results of PRIME II and BIG 2.04 MRC SUPREMO trials	Prof. Dr. Ian Kunkler
Panel of Expert Prof. Dr. Raju Titus Chacko Prof. Dr. Ahmed Sayeed Prof. Dr. Rajesh Balakrishnan Brig. Gen. Prof. Dr. Md Yousuf Ali		

Chairperson

Moderator

Prof. Dr. Md Mokhles Uddin

Dr. Shafatujjahan

11:00 AM - 11:30 AM



SESSION 02

PLENARY 02 | BALL ROOM

Time	Topics	Speaker
11:30 PM - 12:00 PM	Update on systemic therapy for estrogen receptor positive, HER2-negative breast cancer	Prof. Dr. Nicholas Zdenkwoski
12:00 PM - 12:30 PM	Young Women with Breast Cancer and special considerations	Dr. Tan Si Ying
12:30 PM - 01:00 PM	YoWo - the young woman's programme	Dr. Ma Jun
Danel of Expert	Prof. Dr. Salma Sultana Maj. Gen (RTD) Pro	f. Dr. Md. Azizul Islam

Prof Dr. Kazi Manzur Kader | Dr. Md. Jahangir Kabir

Chairperson

Moderator

Prof. Dr. Parveen Shahida Akhtar

Dr. Lubna Mariam

01:00 PM - 02:30 PM (LUNCH & PRAYER



01.00 PM - 02.30 PM

POSTER PRESENTATION

Panel of Expert

Dr. Md. Zaker Ullah | Dr. Ferdous Ara Begum Dr. Hasan Murshed | Dr. Md. Salim Reza

SESSION 03 | ADVANCED BREAST CANCER PARALLEL 1 | BALL ROOM 01

Time	Topics	Speaker
02:30 PM - 03:00 PM	Management of Non Metastatic Her 2 Over-expressed Breast Cancer	Dr. See Hui Ti
03:00 PM - 03:30 PM	Pembrolizumab for Early Triple-Negative Breast Cancer	Dr. Peter Schimd
03:30 PM - 04:00 PM	Hypofraction for Breast Radiotherapy	Prof. Dr. Grace Kusumawidjaja
Panel of Expert	Panel of Expert Prof. Brig Gen (RTD) Dr. Md Quadrat E Elahi Dr. Ferdous Shahriar Sayed Prof. Dr. Nizamul Haque Lt. Col. Dr. S M Rokonuzzaman	

Chairperson

Moderator

Prof. Dr. Md Mofazzel Hossain

Dr. Bhaskar Chakraborty

SESSION 03 | PERSONALIZED MEDICINE

PARALLEL 2 | BALL ROOM 02

Time	Topics	Speaker
02:30 PM - 03:00 PM	Quality Assurance of Breast Biomarkers Assays in Immunohistochemistry: Adapting Standards for Bangladesh Laboratories	Prof. Dr. Jabed Iqbal
03:00 PM - 03:30 PM	Standard practice in pathological evaluation of RCB in breast specimen	Prof. S M Khodeza Nahar Begum
03:30 PM - 04:00 PM	Plan evaluation in early breast cancer in the era of hypofractionated radiation	Dr. Dodul Mondal

Panel of Expert

Prof. Dr. Md. Ehteshamul Hoque | Prof. Dr. Naziruddin Mollah Prof. Dr. Sajjad Md. Yusuff | Prof. Dr. M Kamal Uddin

Chairperson

Moderator

Dr. Parvin Akhter Banu

Dr. Md Abdul Mannan

SESSION 03 | ORAL ABSTRACT SURGERY & TUMOR BOARD

PARALLEL 3 | PADMA

Topics	Speaker
De-escalating breast and Axillary surgery after neoadjuvant chemotherapy	Dr. Md Zaker Ullah
Experience of Rare Metaplastic Breast Cancer Case series	Prof. Dr. Salma Sultana
Short term outcomes of oncoplastic breast surgery at a tertiary cancer centre in Bangladesh	Dr. Hasan Shahriar Md. Nuruzzaman
Novel Development in Breast Radiotherapy in Bangladesh: Challenges in Intraoperative Radiotherapy by a Breast Onco-surgeon	Dr. Ali Nafisa
Portable ultrasound as an important peri operative tool for surgeons as tumour localization and ensuring tumour free margin during BCS or wide local excision.	Dr. Leea Amin
Survival probabilities of breast cancer patients beyond serial axillary node dissection – A prospective study	Dr. A K Mostaque
Oncoplastic Breast Surgery: Median 36-Month Follow Up Results.	Dr. A K M Minhaj Bhuiyan
Scope of Advanced Breast Cancer Surgery in a Govt. Hospital - A Single Centre Experience	Dr. Sharmin Islam
Comparative Study Between Imprint Cytology and Frozen Section Biopsy for Intraoperative Assessment of Sentinel Lymph Node in Breast Cancer	Dr. Noor E Alam
	De-escalating breast and Axillary surgery after neoadjuvant chemotherapy Experience of Rare Metaplastic Breast Cancer Case series Short term outcomes of oncoplastic breast surgery at a tertiary cancer centre in Bangladesh Novel Development in Breast Radiotherapy in Bangladesh: Challenges in Intraoperative Radiotherapy by a Breast Onco-surgeon Portable ultrasound as an important peri operative tool for surgeons as tumour localization and ensuring tumour free margin during BCS or wide local excision. Survival probabilities of breast cancer patients beyond serial axillary node dissection â€" A prospective study Oncoplastic Breast Surgery: Median 36-Month Follow Up Results. Scope of Advanced Breast Cancer Surgery in a Govt. Hospital - A Single Centre Experience Comparative Study Between Imprint Cytology and Frozen Section Biopsy for Intraoperative Assessment of Sentinel Lymph Node in Breast

Panel of Expert

Prof. Dr. Don S. Dizon | Prof. Dr. Ismail Jatoi Dr. Md. Zaker Ullah | Prof. Dr. A F M Anwar Hossain Prof. Dr. Jabed Iqbal | Prof. Dr S M Khodeza Nahar Begum Dr. Dodul Mondal | Prof Dr Md Golam Mostafa | Prof. Ian Kunkler

Chairperson Moderator

Prof. Dr. Rayhana Awwal Sumi Prof. Dr. Saif Uddin Ahmed Dr. Hasan Shahriar Md Nuruzzaman Kallol Dr. Sharmin Islam

SESSION 03 | MEDICAL PHYSICS

PARALLEL 4 | SURMA

Time	Topics	Speaker
02:30 PM - 02:50 PM	Advances in Breast Cancer Radiotherapy: 3D, photon Arc and Proton Therapy at NCCS	Zubin Russy Master
02:50 PM - 03:05 PM	Radiotherapy for Breast Cancer: A Medical Physicist's Perspective on Precision, Safety, and Quality	Dr. Md Akhtaruzzaman
03:05 PM - 03:15 PM	Al Driven Auto Contouring and Planning for Breast Cancer Radiotherapy: A Feasibility Study on Geometric and Dosimetric Accuracy	Dr. Md Anwarul Islam
03:15 PM - 03:25 PM	Experience of Hybrid Planning Technique in Breast Cancer Radiotherapy	Mr. Md Abu Kausar
03:25 PM - 03:35 PM	Development of a Cost-Effective Homemade Device as an Alternative to MRI Breast Coils for Breast Cancer Detection	Mr. Md Mokhlesur Rahman
03:35 PM - 03:45 PM	Free-Breathing VMAT and IMRT versus Deep Inspiration Breath-Hold 3D-CRT Techniques for Left-Breast Cancer: A Cost-Effective and Practical Solution for Developing Countries	Mr. Md Jobairul Islam
03:45 PM - 03:55 PM	Effect of Bolus in Post-Mastectomy Chest-Wall Irradiation: A Retrospective Cross-sectional Study	Mr. Md Fajle Rabby

Panel of Expert

Dr. Md Rashid Un Nabi | Dr. Muhammad Masud Rana Dr. Md Akhtaruzzaman

Chairperson Moderator

Prof. Dr. Golam Abu Zakaria
Prof Dr Hasin Anupama Azhari

Dr. Jannatul Ferdause

SESSION 04 | PERSONALIZED MEDICINE

PARALLEL 1 | BALL ROOM 01

Time	Topics	Speaker
04:30 PM - 05:00 PM	Cancer Genomic Medicine : Lessons in Implementation	Dr. Joanne Ngeow Yuen Yie
05:00 PM - 05:30 PM	Treatment of metastatic breast cancer; The case for precision medicine	Prof. Dr. Paul Mainwaring
05:30 PM - 06:00 PM	Is BCS Safe in TNBCs	Dr. Amar Deshpande
Prof Dr Md Abul Absan Didar Dr Shahida Alam Lima		Alam Lima

Panel of Expert

Dr. A F M Kamal Uddin | Dr. Ali Asgor Chowdhury Dr. Sadia Sharmin

Chairperson	Moderator
Prof. Dr. Syed Md Akram Hussain	Dr. Rubama Karim

SESSION 04 | ORAL ABSTRACT

PARALLEL 2 | BALL ROOM 2

Time	Topics	Speaker
04:30 PM - 4:45 PM	Port-A-Cath: A Real Life Study in Patients Receiving Chemotherapy â€" Single Centre Experience, to Access Efficacy, Safety & Impact on Quality of Life	Dr. Faisal Shahriar
04.45 PM - 5.00 PM	Clinico-Demographic Characteristics of CA 15-3 Biomarker Positive Recurrent Breast Carcinoma Patients	Dr. Rawnok Jahan Kabir
05.00 PM - 5.15 PM	Evaluating the Success of Current Standard of Care in Breast Cancer Treatment: A Retrospective Study in Bangladesh	Dr. Arifur Rahman
05.15 PM - 5.30 PM	Hypofractionated radiotherapy for 5 week 50 gy versus 3 week 40 gy in locally advanced Breast cancer in Bangladeshi woman of breast cancer at a tertiary level hospital in Bangladesh.	Dr. Rowshon Ara Begum
5.30 PM-5.45 PM	Hypofractionated Radiotherapy in Post Operative Breast Cancer Patients. 03 Years Clinical Experience in a Newly Established Cancer Center	Dr. Shaila Sharmin
5.45 PM-6.00 PM	Real-Life Retrospective Single-Arm Study of Postpartum Breast Cancer: Epidemiological Insights into Uncommon and Critical Cases in Bangladesh	Dr. Suriana Sultana
Danol of Export	Prof. Dr. Tapesh Kumar Paul Dr. A K M Min	haj Uddin Bhuiyan

Dr. Ashim Kumar Sengupta | Dr. Biswajit Bhattacharjee

Moderator

Prof. Dr. Md Moarraf Hossen

Dr. Shamima Afroz Trina

SESSION 04 | SURGERY TUMOR BOARD CONTINUE

PARALLEL 3 | PADMA

Time	Topics	Speaker
04:00 PM - 04:30 PM	Challenging case with Fibromatosis Breast Cancer	Dr. Hasan Shahriar Md Nuruzzaman Kallol
04.30 PM-05.00 PM	De-Novo metastatic Her 2 Breast Cancer with complete radiological response of initial management	Dr. Ayesha Siddiqua
05:30 PM-06:00 PM	Pretreated case with local failure of synchronus bilateral breast	DMCH
	Prof. Dr. Don S. Dizon Prof. Dr. Ismail Jatoi	

Panel of Expert

Prof. Dr. Don S. Dizon | Prof. Dr. Ismail Jatoi Dr. Md. Zaker Ullah | Prof. Dr. A F M Anwar Hussain Prof. Dr. Jabed Iqbal | Prof. Dr. S M Khodeza Nahar Begum Dr. Dodul Mondal | Prof. Dr. Mohammad Golam Mostafa Prof. Dr. Ian Kunkler

Chairperson

Moderator

Prof. Dr. Rayhana Awwal Sumi

Dr. Hasan Shahriar Md Nuruzzaman Kallol Dr. Ayesha Siddiqua

SESSION 04 | ORAL ABSTRACT (BASIC SCIENCE)

PARALLEL 3 | SURMA

(BASIC SCILITOL)		
Time	Topics	Speaker
04:30 PM - 04:45 PM	Effect of XRCC1 Gene Polymorphism (rs1799782) on Response and Toxicities of Chemotherapy in Bangladeshi Breast Cancer Patients	Md. Shihad Al Shariar
04:45 PM - 05:00 PM	Breast Cancer Detection with Explainable Al: Grad-CAM and Bounding Box-Based Interpretability	Samrat Kumar Dev Sharma
05:00 PM - 05:30 PM	Importance of Genetic Testing in Triple Negative Breast Cancer: Insights from a real-life cohort	Germany
05:30 PM - 05:45 PM	Multimodal AI for Breast Cancer Diagnosis: Precision Segmentation and Comprehensive Report Generation from Mammograms.	Dr. Monir
	Prof Dr Nazrina Khatun Prof Dr Rakib Ud	ldin Ahmed

Panel of Expert

Prof. Dr. Nazrina Khatun | Prof. Dr. Rakib Uddin Ahmed Dr. Jahan Afroza Khanam Lucky


Chairperson

Dr. Hasan Murshed


Moderator


Dr. Ishtiag Ur Rahim

Grand Ballroom Layout



ROOM LAYOUT





ABSTRACTS



DR. NICHOLAS ZDENKOWSKI
BMed, FRACP, PhD
Medical Oncologist, Hunter
Valley Oncology
Newcastle Australia
Conjoint Senior Lecturer
University of Newcastle, Australia

Update on systemic therapy for early stage estrogen receptor positive, HER2-negative breast cancer

Progress has been made recently in the management of estrogen-receptor positive, HER2-negative early stage breast cancer. This is reflected in reductions in recurrence and death from breast cancer. Decisions about treatment have become more complex. The emergence of data to support adjuvant CDK 4/6 inhibitors is being incorporated into routine practice. It has become more clear which patients will benefit from adjuvant chemotherapy, although the tools that we use remain imprecise and may not be accessible to all. Adjuvant zoledronic acid is a relatively low-cost strategy that is supported by data, but the implementation is variable. Duration of, and type of optimal endocrine therapy according to tumour and patient variables, will be presented. Clinical trials and the early data for neoadjuvant therapy with and without immunotherapy will also be discussed.



DR. SEE HUI TISenior Consultant
Medical Oncologist
Parkway Cancer Centre
Singapore

Management of Non Metastatic Her 2 Over-expressed Breast Cancer

With the advent of breast cancer screening we are picking up earlier cancers and increasing the chance of cure for patients with aggressive breast cancer. Dr See shall be sharing a summary of treatment options for patients with non metastatic Her2 over expressed breast cancer and illustrating it with a few case studies.



PROF. DR. PAUL MAINWARING MBBS, MD, FRACP Co-Founder Executive Chairman & CEO XING Group Holdings Pty Ltd Brisbane, QLD Australia Consultant, Medical Oncologist ICON Cancer Care

Treatment of metastatic breast cancer; The case for precision medicine

The hope after the sequencing of the human genome was that by defining disease in terms of its molecular make up novel therapeutics could be developed to treat, prevent and screen for diseases. Cancer is the leading paradigm of this approach with over 100 anti-cancer agents approved by the FDA, but not all of which are cost-effective. Arguably breast cancer was the first disease that was targeted by alterations in its molecular make up (ER biology), initially by adrenalectomy, but in the 1970s by tamoxifen, 1980s aromatase inhibitors and more recently the CDK 4/6 inhibitors, which are now being used in the curative setting.

In the metastatic breast cancer (MBC) setting, it can be strongly argued that all cancers should undergo molecular screening for breast specific aberrations such as ESR1 mutations, PIK3CA/PTEN/AKT aberrations, somatic and germline aberrations in the homologous recombination deficiency genes, e.g. BRCA1/2, as well as the updated implications of protein HER2, ER, PgR and PD-L1 expression.

As metastatic disease progresses, further clonal heterogeneity is also important for second line and beyond therapies as MBC will acquire one or more of these common aberrations, as well as currently undruggable targets such as TP53 for which numerous clinical trials are underway as well as finally rare agnostic targets, MSI, HER2mu, NTRK which are also druggable. Naturally, each of these different pathways starts from the initial molecular sub type and hence we now have algorithms for first second and third line therapies for each of these.

I will share some of the challenges of building the infrastructure from a laboratory, hardware as well as software point of view in order to deliver ISO15189 accredited molecular pathology reports bringing first world medicine rapidly and at an affordable cost to Bangladeshi breast cancer patients in 2025



PROF. DR. IAN KUNKLER Consultant Clinical Oncology Edinburgh Cancer Centre University of Edinburgh, Edinburgh, Scotland, UK

Update on adjuvant radiotherapy for early breast cancer

De-escalation is one of the themes of contemporary adjuvant radiotherapy (RT) for early breast cancer. Omission of postoperative RT after mastectomy in 'intermediate -risk' breast cancer and after breast conserving surgery (BCS) among 'low risk' older patients have long been controversial. The CALBG 9343 and PRIME II trials have provided an evidence base for the option of omission of RT in older, ER positive patients treated with BCS and adjuvant endocrine therapy (AET), influencing international guidelines. The EUROPA trial is comparing adjuvant RT alone to AET alone in older, small, ER +. HER2 negative tumours after BCS. There is also interest in the testing of molecular markers to predict which 'low risk,' ER positive, HER 2 negative older patients are likely to benefit from adjuvant RT after BCS and AET. There are a number of candidate molecular signatures of breast cancer radiosensitivity of which POLAR (Profile for Omission of Adjuvant Radiotherapy) is a leading candidate. Additional validation will be required before clinical implementation can be considered.

Indications for postmastectomy radiotherapy (PMRT) have been strongly influenced by the landmark RCTs from the Danish and Canadian trial groups demonstrating a 9-10% 10 year survival benefit of loco-regional PMRT in 'high risk ' premenopausal and postmenopausal patients treated by mastectomy and adjuvant systemic therapy and reported in the late 1990s. The 2014 EBCTCG meta-analysis showed that PMRT reduced first recurrence with a modest improvement in 15 year survival. However the landscape of breast cancer management has changed substantially over the last three decades with better screening, surgery, radiotherapy and systemic therapy associated with falling breast cancer mortality. At the same time RT dose fractionation regimes have been shortening. The BIG 2.-04 MRC SUPREMO trial evaluating the role of chest wall irradiation after mastectomy and modern systemic therapy on 10 year overall survival in 'intermediate-risk' operable breast cancer with 1-3 positive axillary nodes or node negative with other risk factors recently reported it smain results at the 2024 San Antonio Breast Cancer Symposium. Its findings may influence surgical and radiotherapeutic guidelines and practice.



DR. DODUL MONDAL
Director & Clinical Administrator
Department of Radiation
Oncology
Max Super Speciality Hospital
Saket, Delhi, India

Plan evaluation in early breast cancer in the era of hypofractionated radiation

Breast cancer is the commonest cancer among women worldwide leading to significant disease burden. With progress in treatment, the outcome has improved and the issue of QOL has become more significant. In countries and centers with resource constraints, a hypofractionated regime provides better access to cancer care. Target and OAR dose vary significantly between a conventional, hypofractionated and extremely hypofractionated regime. Thus, it becomes very important to understand how to evaluate a plan in such a scenario.

Before understanding plan evaluation, it is important to understand concept of target coverage and OAR doses. Various types of plan evaluation include qualitative and quantitative plan evaluation. Several indices used to describe target coverage include conformity index (CI), Homogeneity Index (HI), Target Coverage Index (TCI) etc. Dose volume histogram (DVH) analysis is an important aspect of plan evaluation and radiation oncologists should be well aware of various types of DVH analysis methods.

It is also worth noting that various trials and protocols have used different criteria to analyze DVH. Evry center and user will require to decide and establish a particular protocol to be followed to make the entire workflow smooth and streamlined. This will improve patient safety and QOL.



PROF. DR. S. M. KHODEZA NAHAR BEGUM Consultant Pathology Bangladesh Specialized Hospital

Standard practice in pathological evaluation of RCB in breast specimen

The use of neoadjuvant therapy in managing early-stage invasive breast cancer is on the rise. There is a need to standardize the evaluation of post-neoadjuvant therapy breast specimens in routine clinical practice. Tools such as Residual Cancer Burden (RCB) utilize pathological characteristics of treated tumors to assess long-term outcomes. Neoadjuvant chemotherapy requires a thorough understanding of the specimen, along with knowledge of the patient's clinical disease, radiologic findings, and treatment course. Effective communication between specialists is crucial in optimizing patient care.

Reconstructing the gross, radiologic, and histopathologic findings is essential for estimating the Residual Cancer Burden (RCB). As pathologists, our role is critically important to our clinical colleagues and, most importantly, to the patients they treat. Therefore, our aim is to provide the most structured and valuable information possible.

This discussion aims to emphasize the importance of a unified approach to standardizing the grossing and reporting of breast specimens in the neoadjuvant setting, ultimately improving patient outcomes.



MR. ZUBIN RUSSY MASTER
Sr. Principal Radiation Physicist
National Cancer Centre
Singapore

Advances in Breast Cancer Radiotherapy: 3D, photon Arc and Proton Therapy at NCCS

This talk will provide an overview on the current standard of care for breast radiotherapy at NCCS, briefly covering 3D Conformal RT and Volumetric Modulated Arc Therapy, and will highlight the key planning techniques and considerations for these approaches. We will then transition to discussing the rationale for adopting proton radiotherapy in the management of breast cancer, and in particular, emphasize how the dosimetric properties of protons can improve target coverage, achieve improved cardiac and lung sparing, reduce contralateral breast exposure and reduce risks of secondary malignancies — especially in complex clinical scenarios, and we will briefly discuss our journey to start a proton breast trial and get proton therapy approved for the treatment of breast cancers in NCCS.



PROF. RAJESH BALAKRISHNAN
MD, DNB
(Radiation Oncology)
Professor and Head of Unit III
Department of Radiation Oncology
Christian Medical College
Vellore, India

Radiation Escalation and De-escalation Strategies in Breast Cancer in 2024

Radiation therapy is a critical component of breast cancer treatment, often used in conjunction with surgery and systemic therapies. The strategies for radiation therapy are continuously evolving, with a focus on optimizing outcomes by either escalating or de-escalating treatment based on individual patient risk factors and disease characteristics. This document explores the current approaches to radiation therapy in breast cancer, emphasizing the concepts of escalation and de-escalation. Understanding Adjuvant Radiotherapy Adjuvant radiotherapy is administered after surgery to eliminate any residual cancer cells, reducing the risk of local recurrence and improving overall survival. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) has provided substantial evidence supporting the use of adjuvant radiotherapy. Studies have shown that radiotherapy significantly reduces local recurrence rates and can lead to modest improvements in overall survival, particularly for higher-risk patients. The survival benefit is dependent on the molecular subtype of breast cancer. For example, patients with Luminal A subtype tend to have better survival rates compared to those with triple-negative breast cancer. Radiotherapy Protocols in Breast Cancer Radiotherapy is a key component of treatment for early breast cancer (EBC) and locally advanced breast cancer (LABC), with distinct protocols: • EBC -Upfront Surgery: Patients undergoing breast-conserving surgery (BCS) require whole-breast irradiation, while post-mastectomy radiotherapy (PMRT) is indicated in those with high-risk features, such as four or more positive nodes, gross residual disease, or positive margins. • EBC -Post-Neoadjuvant Chemotherapy (NACT): Patients with ER-negative and HER2-positive disease typically receive radiotherapy to the chest wall and supraclavicular lymph nodes, with individualized axillary and internal mammary chain (IMC) treatment. · LABC - Post-NACT: Post-mastectomy radiotherapy is standard for all patients, while select T1/T2N0 cases may be spared RT following multidisciplinary team discussions. Nodal Irradiation: Nodal RT is considered for patients with T3/T4 tumors, positive nodes, or residual nodal disease post-NACT.



PROF. DR. MD ZAKER ULLAH
Consultant
Oncoplastic Breast & General Surgeon
The Harley Street Clinic
The Holly Private Hospital
Barts Health NHS Trust

De-escalating breast and Axillary surgery after neoadjuvant chemotherapy



PROF. DR. JABED IQBALAssociate Professor
Senior Consultant
Department of Anatomical Pathology
Singapore General Hospital

Personalized Medicine - Pathology



PROF. DR. GRACE KUSUMAWIDJAJA
Professor
Consultant
Radiation Oncology
National Cancer Centre, Singapore

Hypofraction for Breast Radiotherapy



DR. PETER SCHIMDFRCP, MD, PhD
Professor of Cancer Medicine
Royal college of Physicians
Centre lead, Group leader

Pembrolizumab for Early Triple-Negative Breast Cancer



DR. MA JUNConsultant
Division of Medical Oncology
National Cancer Centre
Singapore

YoWo - the young woman's programme



DR. TAN SI YINGConsultant Surgical Oncologist
in the Department of Breast Surgery
in both Singapore General
Hospital and National Cancer Centre,
Singapore

Young Women with Breast Cancer and special considerations

MEDICAL PHYSICS

SESSION 03 | MEDICAL PHYSICS

PARALLEL 4 | SURMA

Panel of Expert

Dr. Md Rashid Un Nabi | Dr. Muhammad Masud Rana Dr. Md Akhtaruzzaman

	Chairperson	Moderator
Prof. Dr. Golam Abu Zakaria Prof Dr Hasin Anupama Azhari		Dr. Jannatul Ferdause
SL	AUTHOR	ABSTRACT TITLE
01.	Dr. Md Akhtaruzzaman	Radiotherapy for Breast Cancer: A Medical Physicist's Perspective on Precision, Safety, and Quality
02.	Dr. Md Anwarul Islam	Al Driven Auto Contouring and Planning for Breast Cancer Radiotherapy: A Feasibility Study on Geometric and Dosimetric Accuracy
03.	Mr. Md Abu Kausar	Experience of Hybrid Planning Technique in Breast Cancer Radiotherapy
04.	Mr. Md Mokhlesur Rahman	Development of a Cost-Effective Homemade Device as an Alternative to MRI Breast Coils for Breast Cancer Detection
05.	Mr. Md Jobairul Islam	Simultaneous Integrated Boost vs. Sequential Boost in Breast Cancer Radiotherapy: A Comprehensive Analysis of Dosimetric, Radiobiological, and Cost-Effectiveness
06.	Mr. Md Fajle Rabby	Effect of Bolus in Post-Mastectomy Chest-Wall Irradiation: A Retrospective Cross-sectional Study

POSTER

POSTER PRESENTATION

Panel of Expert

Dr. Md. Zaker Ullah | Dr. Ferdous Ara Begum Dr. Hasan Murshed | Dr. Md. Salim Reza

SL	AUTHOR	ABSTRACT TITLE
01.	Md. Mokhlesur Rahman Md. Jobirul Islam Sirajum Munira	Dosimetric Comparison of Bolus and Non-Bolus Techniques in Post-Mastectomy Breast Radiotherapy
02.	Dr. Purnopama Puja Prof. Dr. Ashim Kumar Ghosh	Male Breast Cancer: An Unfolding Challenge in Recurrence and Treatment Gaps
03.	Kazi Masrukh Rahman Empiat Zahan Hazari Efti	In Silico investigation on the inhibitory activity of compounds found in Manuka Honey against MCF-7 cancer cell line and design of potential lead compounds by pharmacophore modeling
04.	Shouruv Biswas Md. Masudur Rahman Sarwar Alam	Weekly Versus Three Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2- negative, Stage III Breast Cancer: A comparison of treatment response
05.	Dr. Labannya Das Pura	Immunotherapy for breast cancer : a review of present and future perspectives
06.	Dr. Sura Jukrup Momtehena	Determinants of Triple-Negative Breast Cancer: The Influence of Age and Contraceptive Use in Bangladesh.
07.	Md. Siddiqul Islam Jubayar Hosen Krishno Dutta	Effects of ABCB1 gene polymorphism on toxicity of Taxene-based Chemotherapy in Bangladeshi Triple Negative Breast Cancer patients.
08.	Rashika T. Mallick R H Lania SAC Alamgir H M	Assessment and comparison of prevalence of breast cancer risk factors and associated awareness in women living in urban and rural settings in Bangladesh
09.	Dr. Anabil Digama	Inflammatory Breast Cancer: Challenges in the Management
10.	Lt Col (Dr.) Nasir Uddin	The effect of the XRCC1 gene polymorphism (rs25487) on the etiology of breast cancer in the Bangladeshi population.
11.	Jubayer Hosen Md. Shihad Al Shariar Lamia Akhter	Breast Cancer Recovery through advance sensory technology

ORAL ABSTRACTS

Moderator

Panel of Expert

Chairperson

Prof. Dr. Tapesh Kumar Paul | Dr. A K M Minhaj Uddin Bhuiyan Dr. Ashim Kumar Sengupta | Dr. Biswajit Bhattacharjee

Prof. Dr. Md Moarraf Hossen		модегатог Dr. Shamima Afroz Trina
SL	AUTHOR	TITLE
01.	Faisal SM Rahman MA Chowdhury QZ Begum FA Shiddika A	Port-A-Cath: A Real Life Study in Patients Receiving Chemotherapy â€" Single Centre Experience, to Access Efficacy, Safety & Impact on Quality of Life
02.	Rawnok Jahan Kabir Refoyez Mahmud Md. Enamul Kabir Abdullah Md Abu Ayub Ansary Salma Sultana	Clinico-Demographic Characteristics of CA 15-3 Biomarker Positive Recurrent Breast Carcinoma Patients
03.	Dr. Md Arifur Rahman	Evaluating the Success of Current Standard of Care in Breast Cancer Treatment: A Retrospective Study in Bangladesh
04.	Prof. Dr. Rowshan Ara Begum Dr Sura Jukrup Momtahena Dr Aditi Paul Chowdhury	Hypofractionated radiotherapy for 5 week 50 gy versus 3 week 40 gy in locally advanced Breast cancer in Bangladeshi woman of breast cancer at a tertiary level hospital in Bangladesh.
05.	Dr. Shaila Sharmin Yousuf Ali SM Rokonuzzaman Nazat Sultana Ashequzzaman Anower Hossain Ibrahim Naser Isrtat Sultana Iffat Sharmin	Hypofractionated Radiotherapy in Post Operative Breast Cancer Patients. 03 Years Clinical Experience in a Newly Established Cancer Center
06.	Dr. Naheed Rukhsana Dr. Suriana Sultana	Real-Life Retrospective Single-Arm Study of Postpartum Breast Cancer: Epidemiological Insights into Uncommon and Critical Cases in Bangladesh

OTHER ABSTRACTS

01.	Md. Siddiqul Islam Salma Parvin Ferdin Ehsan Zannatul Tunjum Islam Umme Rokaya Keya Krishno Dutta1 Tanvir Mamun Rumy Jubayer Hosen Yesmin Begum1 Hrishik Iqbal Abu Syed Md. Mosaddek Kazi Asharaful Islam Md. Waheed Aktar	Influence of MRP1 and MDR1 Gene Variants on Chemotherapy Outcomes in Breast Cancer Patients
02.	Md. Anwarul Islam S M Hasibul Hoque Md. Eshtiaqul Haque Asim Kumar Paul Md. Abdus Sabur	Al Driven Auto Contouring and Planning for Breast Cancer Radiotherapy: A Feasibility Study on Geometric and Dosimetric Accuracy.
03.	Md. Mokhlesur Rahman	Development of a Cost-Effective Homemade Device as an Alternative to MRI Breast Coils for Breast Cancer Detection
04.	Leea Amin Jannatul Ferdause Rifat Rubama Karim Adity Paul Chowdhury Samina Jafar Khaleque Arif Rabeya Khandaker Trisha	Portable ultrasound as an important peri operative tool for surgeons as tumour localization and ensuring tumour free margin during BCS or wide local excision.
05.	Dr. A K M Minhaj Bhuiyan Dr. Hasan Shahriar Md. Nuruzzaman	Oncoplastic Breast Surgery: Median 36-Month Follow Up Results.
06.	Md. Shihad Al Shariar Jubayer Hosen Lamia Akther Mahmud Hasan Rifat Tanjum Akter Keya Tanvir Mamun Rumy Subrota Sutradhar Ferdowsi Akter Israt Jahan Bulbul Yesmin Begum Abu Syed Md. Mosaddek Kazi Ashraful Islam Md. Siddiqul Islam	Effect of XRCC1 Gene Polymorphism (rs1799782) on Response and Toxicities of Chemotherapy in Bangladeshi Breast Cancer Patients

07.	Prof. Dr. S M Khodeza Nahar Begum	Standard practice in pathological evaluation of RCB in breast specimen
08.	Sharmin Islam Sadia Afrin Tani Mst Jesmen Nahar Fahimul Islam Mondol Prof. Salma Sultana	Scope of Advanced Breast Cancer Surgery in a Govt. Hospital - A Single Centre Experience
09.	Noor-E-Alam Salma Sultana Mashud Parvez Swapnil Roy Mohammad Asad Ullah Md. Fahimul Islam Mondal Mohammad Masum Md. Mehfujul Hassan Sadia Soruvi Mir Md. Ashraful Islam	Comparative Study Between Imprint Cytology and Frozen Section Biopsy for Intraoperative Assessment of Sentinel Lymph Node in Breast Cancer
10.	Nuruzzaman Hasan Shahriar Md. Bhuiyan A K M Minhaj Uddin Islam, Md. Johirul Ullah Md. Zaker	Short term outcomes of oncoplastic breast surgery at a tertiary cancer centre in Bangladesh
11.	A. K. Mostaque A. M. M. Shariful Alam M. Kamal	Survival probabilities of breast cancer patients beyond serial axillary node dissection – A prospective study
12.	Ali Nafisa	Novel Development in Breast Radiotherapy in Bangladesh: Challenges in Intraoperative Radiotherapy by a Breast Onco-surgeon
13.	Dr Monir, NSU	Multimodal Al for Breast Cancer Diagnosis: Precision Segmentation and Comprehensive Report Generation from Mammograms.
14.	Samrat Kumar Dev Sharma	Breast Cancer Detection with Explainable Al: Grad-CAM and Bounding Box-Based Interpretability
15.	Prof Dr. Salma sultana	Surgical Management of Metaplastic Breast Cancer: A Retrospective Analysis

BANGLADESH BREAST CANCER CONFERENCE

MEMORIES 2015









































BANGLADESH BREAST CANCER CONFERENCE

MEMORIES 2017





















BANGLADESH BREAST CANCER CONFERENCE MEMORIES 2019

























CONTINUOUS MEDICAL EDUCATION (BREAST AND LUNG)

BREAST

Cancer Awareness



Prof. Dr. Nadia Harbeck
Collaborative decision making in
HER2+ Neoadjuvant Breast Cancer



Dr. Maria Vidal Adjuvant Treatment in HER2+ eBC Patient: Selecting the Standrad Option



Prof. Dr. Martine J.Piccart Gebhart Recommendations for the identification and treatment of HER2-positive Metastatic breast cancer











Welcome to the Lung Cancer Expert Series 2022, a series of live and interactive 1-hour webinars, will be presented by a faculty of world-leading multidisciplinary Lung cancer experts. These sessions will discuss relevant Lung cancer topics and offer a fantastic opportunity for you to interact with our esteemed faculty through live Q&A sessions.



cl

Session

Cancer Immunotherapy: Immune checkpoints across line of metastatic NSCLC

11 March 2022 | Time: 3:30 - 5:00 pm (BST)

Fmgd Dawoud

5















Lung Cancer Expert Series 2022






















BANGLADESH SOCIETY FOR BREAST CANCER STUDY & GLOBAL CANCER INSTITUTE

JOINT COLLABORATION BREAST TUMOR BOARD





ANNUAL GENERAL MEETING (AGM)























PRECEPTORSHIP PROGRAM-01

PROGRAM SCHEDULE

Day - 1 : 4 th March 2021 (Thursday)				
Arrival and Evening Tea	05:30 PM			
Welcome Address	06:00 - 06:05 PM	Prof. Qamruzzaman Chowdhury		
Inauguration	06:05 - 06:10 PM	Prof. M A Hai		
Basic Imaging of Breast Cancer	06:10 - 07:00 PM	Dr. Sharmin Akhtar Rupa		
ABC 5 Guideline & Management of HR+ Breast Cancer	07:00 - 08:00 PM	Prof. Fatema Karduso		
Understanding the Basic Pathology of Breast Cancer	08:00 - 08:45 PM	Prof. S.M Khodeza Nahar Begum		
How to Read a PET CT Report	08:45 - 09:15 PM	Dr. Rawnak Afrin		
Dinner	09:30 PM			

Day - 2 : 5 th March 2021 (Friday)				
Breakfast	08:00 - 09:00 AM			
Hypofractionation in Breast Radiotherapy	09:00 - 09:40 AM	Prof. Tabassum Wadasadawala		
Essentials of Breast Cancer Surgery	09:40 - 10:10 AM	Dr. Garvit Chitkara		
Recent Advances in Breast Cancer Surgery	10:10 - 10:40 AM	Dr. Shalaka P Joshi		
Tea Break	10:40 - 11:10 AM			
Plan Evaluation in Breast Radiotherapy	11:10 - 11:50 AM	Prof. Rajesh Balakrishnan		
Management of TNBC	11:50 AM - 12:30 PM	Prof. Dr. Jyoti Bajpai		
Cardiac Sparing Breast Radiotherapy	12:30 - 01:00 PM	Dr. Angela Gaerlan Tagle		
Lunch & Prayer Break	01:00 - 02:30 PM			
Target Volume Delineation in Breast Cancer	02:30 - 03:00 PM	Dr. Kitwadee Saksornchai		
Contouring & Plan Evaluation Workshop Contouring Presentation by participants Group Work	03:00 - 04:30 PM	Prof. Tabassum Wadasadawala Prof. Rajesh Balakrishnan Dr. Reena Phurailatpam		
Tea Break	04:30 - 05:00 PM			
HER2+ MBC	05:00 - 06:00 PM	Dr. Evandro de Azambuja		
Precision Oncology for Breast cancer	06:00 - 07:00 PM	Dr. Ben Ho Park		
HER2+ Breast Cancer: Overview of Management	07:00 - 08:00 PM	Prof. Dr. Don S. Dizon		
Closing & Vote of Thanks	08:00 PM	Dr. Md Salim Reza		
Cultural Program	08:00 - 09:00 PM			
Dinner	09:00 - 10:00 PM			







PRECEPTORSHIP PROGRAM-02

Day - 1 : 25 th November 2021 (Thursday)				
Arrival and Evening Tea	05:30 PM			
Welcome Address	06:00 - 06:05 PM	Prof. Qamruzzaman Chowdhury		
Inauguration	06:05 - 06:10 PM	Prof. M A Hai		
Basic Imaging of Breast Cancer	06:10 - 07:00 PM	Dr. Sharmin Akhtar Rupa		
ABC 5 Guideline & Management of HR+ Breast Cancer	07:00 - 08:00 PM	Prof. Fatema Karduso		
Understanding the Basic Pathology of Breast Cancer	08:00 - 08:45 PM	Prof. S.M Khodeza Nahar Begum		
How to Read a PET CT Report	08:45 - 09:15 PM	Dr. Rawnak Afrin		
Dinner	09:30 PM			

Day - 2 : 26 th November 2021 (Friday)				
Breakfast	08:00 - 09:00 AM			
Hypofractionation in Breast Radiotherapy	09:00 - 09:40 AM	Prof. Tabassum Wadasadawala		
Essentials of Breast Cancer Surgery	09:40 - 10:10 AM	Dr. Garvit Chitkara		
Recent Advances in Breast Cancer Surgery	10:10 - 10:40 AM	Dr. Shalaka P Joshi		
Tea Break	10:40 - 11:10 AM			
Plan Evaluation in Breast Radiotherapy	11:10 - 11:50 AM	Prof. Rajesh Balakrishnan		
Management of TNBC	11:50 AM - 12:30 PM	Prof. Dr. Jyoti Bajpai		
Cardiac Sparing Breast Radiotherapy	12:30 - 01:00 PM	Dr. Angela Gaerlan Tagle		
Lunch & Prayer Break	01:00 - 02:30 PM			
Target Volume Delineation in Breast Cancer	02:30 - 03:00 PM	Dr. Kitwadee Saksornchai		
Contouring & Plan Evaluation Workshop	<u></u>	Prof. Tabassum Wadasadawala		
Contouring Presentation by	03:00 - 04:30 PM	Prof. Rajesh Balakrishnan		
participants Group Work		Dr. Reena Phurailatpam		
Tea Break	04:30 - 05:00 PM			
HER2+ MBC	05:00 - 06:00 PM	Dr. Evandro de Azambuja		
Precision Oncology for Breast cancer	06:00 - 07:00 PM	Dr. Ben Ho Park		
HER2+ Breast Cancer: Overview of Management	07:00 - 08:00 PM	Prof. Dr. Don S. Dizon		
Closing & Vote of Thanks	08:00 PM	Dr. Md Salim Reza		
Cultural Program	08:00 - 09:00 PM			
Dinner	09:00 - 10:00 PM			





SCREENING PROGRAM















BBCC 2022























CRC MANAGEMENT EVENT















































3rd PRECEPTORSHIP PROGRAM ON SARCOMA









































CONTRIBUTORS














































EVENT PARTNERS

PLATINUM







GOLD












SILVER













Innovations of F. Hoffmann-La Roche Ltd.





TACHTEE's Goodstal layesteen IP
Promotions of Accounting Commission of C as a single agent. Prostate Cander's hiormore refractory metastatic prostate cancer doctaxed is administrated as 7 Significal event y a weeks and prednisone or prednisolone single only, tracte daly is administrated continuously, Gastric Cancer tho case of advanced pastir, and gastrosephageal junction adenociarionness flow the prostate of the who have not received proc chemotherapy doctaxed is administrated. 75 mg/m2 as a 1 should a 1 hour afforms of blowed by religibatin 75 mg/m2 as a 1 shoul refolation forther of the 1 hour afforms of blowed by religibatin 75 mg/m2 as a 1 shoul refolation forther and the prostate of the prostate of the prostate of the prostate of the should be supported by the prostate of the prostate of the prostate of the should be prostated by the prostate of the prostate of the should be prostated by the prostate of the prostate of the should be prostated by the prostate of the should be prostated by the prostate of the should be prostated by the prostate of the should be should be prostated by the should be prostated by the should be should

one only followed by silluminated 1720 mg/m² per day given a 24-hour continuous control of the plant of the p

neurosaney Jayas and 'or symptoms have been observed and require reduction of dose. Canter. Touting Heart fallare deserved in patients ensoing Tacetee in combination with stratument, particularly Effectively settlings of the combination with stratument, particularly Effectively settlings with expected contents. Cytical models endemed. (AND has been reported in patients treatment of software for a set with other taces of disquared described in patients treatment of ediposed the settle flattered in the content of the combination of the combination of the combination of the settle flattered in patients treatment of ediposed the endem settlement receives the member described in settlement receives and settlement receives the member described in settlement receives the settlement of ediposed the settlement receives the settlement of the combination release to the settlement of the combination of the production of the described in programme, it is not become without content through the combination of t


Synovia Pharma PLC.

A subsidiary of BEXIMCO PHARMA 6/2/A, Segun Bagicha, Dhaka-1000, Bangladesh Tel: +880 9678000777 | Fax: +880 2223380009 www.synoviapharma.com | 😝 synoviapharmaplc





Live boundless







More than 20 years of Global Experience FDA Approved in early and advanced Colorectal Cancer²

Reference: 1. Synovia Data on File 2. Ejoxatin Prescribing Information









Less hospitalization with lower treatment cost

Higher patient convenience



Better safety profile







Synovia Pharma PLC. A subsidiary of BEXIMCO PHARMA 6/2/A, Segun Bagicha, Dhaka -1000, Bangladesh Tel: +880 9678000777 | Fax: +880 2223380009 www.synoviapharma.com| 😭 synoviapharmaplc

Tresoda™
Trastuzumab 420 mg

A sign of hope a promise of new life

Brolizum[™] 100

Pembrolizumab INN 100 mg

The New Age Solution for Cancer Treatment





Transforming Oncology and Hematology with Innovative **Oral Generics**

Available



SOLID TUMORS

ORAL TARGET THERAPIES

Alecnib Capmaxen Sotoken Lorbrexen Adakras ADAGRASIB 200 mg Ta Lung Cancer Daconit Osimert Selcaxen Laronib Repotrex

Breast Cancer & Ovarian Cancer

TUCAXEN **PALBOXEN** TUCATINIB 150 mg Tab PALBOCICLIB 125 mg Can **Alpesib**

Capivast

RÍBOKIS

Taláparib

Olanib

Olanib

Niranib

Liver Cancer

Caboxen Lenvaxen

Wepanib

Renal Cell Carcinoma

TIVOXEN Caboxen

Pazorest PAZOPANIR 200 mm Tah

Prostate & Colorectal





FRUQUIN FRUQUINTINIB 5 mg Cap

Erdafixen ERDAFITINIB 4 mg Tab

Z A S Corporation Ltd.





VINORELBINE soft capsule 30 mg Vinorelbine (as tartrate)

TO IMPROVE SURVIVAL BY PRESERVING QUALITY OF LIFE



Fulvestrant EVER Pharma Fulvestrant 250 mg







Elevate Confidence Based on Evidence





A REVOLUTION IN CANCER TREATMENT

- √ 1st PD-1 inhibitor
- ✓ US-FDA approved to treat 16 types of advanced cancer
- Median Biosimilar to innovator brand
- Manufactured with RTF API with unique product authentication code






Empowering Immunity, Transforming Lives

- ▼ FDA approved 1st line treatment of mUGI cancer regardless of PD-L1 status
- V Ensures long term survival in Gastroesophageal Cancer
- Approved to treat 10 types of advanced cancer
- W Biosimilar to innovator brand










One Stop Solution For

Helping Physicians To Make Better Clinical Decision









Firoz Tower 152/3-B, 4th Floor, Panthapath, Dhaka 1205.
Phone: +8801742 383 381, +8801685 897 688
Email: masum.rabbani@gmail.com

Taxopac[®]

Taxodoc®





MANUFACTURED in

Dedicated and cutting edge factory

Multiple sterilization steps to ensure Aseptic Process

Impurity tested in accordance to ICH (International Council of Harmonisation)

Fully automated and human touch free production with Advanced Isolator Technology






Committed To Precision For Complete Remission











Renews Hope to Embrace Life

- Proven superiority over Tamoxifen
- Safer and more effective than Letrozole
- Can be consumed for 6 days



The Guiding Light in Breast Cancer

- **♂ Safer than Tamoxifen on long term use**
- ⊗ Superior therapeutic choice as monotherapy & in combination with Abeclib



Jenphar Bangladesh





The First US FDA & EMA approved Biosimilar Trastuzumab and Pegfilgrastim brands in Bangladesh





Continuing the promise of quality in Chemotherapeutic brands














U NOVARTIS

Reimagining medicine, together

We are passionate about discovering new ways to improve and extend people's lives.



Quality API to assure quality outcomes



US DMF Grade API -Ensures Optimum Purity -Assures Quality Outcomes

Aritax | 100 mg Inj.

Quality that Supports the Faith

ricarb | 150 mg Inj.

Platinum Analogue with Better Tolerability

Ariplat | 10 mg Inj. 50 mg Inj.

A Versatile Platinum Chemotherapy

FILGRASTIM USP

An effective solution for Neutropenia



100 & 500 mg Ini.

Bevacizumab INN 100 & 400 mg Inj.





Your Full Spectrum Support

in Breast & Prostet Cancer Treatment



Indications1-4

- Adjuvant therapy for post-menopausal women with HR-positive, early invasive BC
- Adjuvant therapy for post-menopausal women with HR-positive who received 2-3 years of tamoxifen







1 mg tablet

Pre-filled syringe contains 250 mg fulvestrant in a 5 ml solution

 Monotherapy for post-menopausal women with ER-positive, locally advanced, or metastatic BC who did not receive endocrine or relapse or progression after antiestrogen therapy

 In combination with palbociclib for patients with HR-positive, HER2-negative locally advanced or metastatic BC who received prior endocrine therapy 500 mg intramuscular injection once a month

Zoladex 3.6 mg goserelin INN

Pre-filled syringe contains 3.6 mg of goserelin

• For pre- and peri-menopausal women with advanced BC

Alternative to chemotherapy in the standard of care for pre- and peri-menopausal women with ER-positive early BC 3.6 mg depot via SC injection every 28 days



50 mg

- For advanced PC in combination with LHRH or surgical castration
- For patients with locally advanced, non-metastatic PC in whom surgical castration or other intervention is not considered acceptable





Pre-filled syringe contains 3.6 & 10.8 mg of goserelin

- For advanced PC in combination with LHRH or surgical castration
- · For PC patients suitable for hormonal manipulation

3.6 mg: SC injection every 28 days 10.8 mg: SC injection every 12 weeks



Arimidex, anastro: 1 mg tablet



Faslodex, fulvestrant 250 mg solution



Zoladex, goserelin INI 3.6 mg injection



Casodex, bicalutamio



Zoladex, goserelin INN 3.6 & 10.8 mg injection



For full prescribing information, please contact: MGH Healthcare Limited 9° Floor, SKA Tower (Autograph Building), Flot 67 & 68 Kemal Abatuk Avenue, Banani, Dhaka – 1213, BANGLADESH Telsphone: +88-02-56033267-88 (Ext.702)

Document Number: 8D-6416 Approved for Distribution Date: 22/05/2023 Expiry Date: 22/05/202







A combination of 2 monoclonal antibodies (pertuzumab and trastuzumab) in 1 fixed dose SC injection

A new era of treatment for

HER2+ breast cancer patients where innovation meets convenience



Lifting care beyond medicine



Enhanced Safety Reporting for

Pregnancies Exposed to PHESGO

If a pregnant voman is treated with Phesgo, or if a patient becomes pregnant while receiving Phesgo or within 7 months following the last dose of Phiesgo, please immediately report pregnancy to the local floorie. A widness Event Line 1 = 8880 1766696868 and 7 or bangladesh fruguistely groche.com Additional information will be requested during a Phesgo-eposed pregnancy and the first year of the infants life. This will enable Roche to better understand the safety of Phesgo and to provide appropriate information to health authorities, healthcare providers and

erse event with Roche medicinal products please report the adverse event immediately.

-mail-bangladesh.drugsafety⊜roche.com, 24-hour contact no. : +8801766686086 Tirculated with the prior approval of the Directorate Gend of Drug Administration. or any product or therapeutic raare related information and full product information please email at bangladesh.medin-

Phesgo is a trademark of and manufactured for F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel, Switzerland Imported by Radiant Business Consortium Limited, 474 P. Road No 3, Sector 12 Uttara, Dhaka, Bangladesh Reference: Phesgo Product Information December 2020







mins

15 mins

















Striving for Excellence







Achieving Global Excellence in Oncology

- Our commitment towards excellence is going to be recognized with EU-GMP accreditation.
- Since 2014, Healthcare Oncology Ensures world-class quality and safety in cancer treatment.
- . And Now, We are Challenging Our Limits, breaking barriers, Becoming Global.







Conference secretariat

